A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren’s syndrome

0 avis

A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren’s syndrome

Archive ouverte

Edité par CCSD ; Oxford University Press (OUP) -

International audience. This phase 2 proof-of-concept study (NCT02610543) assessed efficacy, safety and effects on salivary gland inflammation of seletalisib, a potent and selective PI3Kδ inhibitor, in patients with moderate-to-severe primary Sjögren's syndrome (PSS).

Langue: en

Indexation

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

A phase II randomised, double-blind, placebo-controlled, proof of concept study of oral seletalisib in patients with primary Sjögren’s syndrome (PSS).

Archive ouverte | Juárez, Maria | CCSD

International audience

Seletalisib for Activated PI3Kδ Syndromes: Open-Label Phase 1b and Extension Studies

Archive ouverte | Diaz, Nieves | CCSD

International audience

Modification of the classification criteria for primary Sjögren syndrome: an international vignette survey

Archive ouverte | Jousse-Joulin, Sandrine | CCSD

International audience

Chargement des enrichissements...